The FDA has issued a Complete Response Letter regarding the NDA for govorestat for the treatment of classic galactosemia.
Geriatric care for LGBTQ+ adults who live in rural communities requires cultural competence training and diverse health care teams.
About one-third of US adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...
Denifanstat treatment significantly improves liver disease activity among individuals with metabolic dysfunction-associated steatohepatitis.
For low-risk pregnancies, planned home births are as safe as planned birth center births, according to a study published.
Diabetic retinopathy screening with AI was associated with higher referral rates to optical coherence tomography but remains underutilized.
Heart failure outcomes in patients with type 2 diabetes receiving once-weekly exenatide are affected by left ventricular ejection fraction.
Long-term sex hormone treatment in transgender individuals can lead to significant changes in body composition and risk factors for cardiovascular disease.
Current prenatal multivitamin and mineral (PMVM) labels are misleading and often exclude the presence of heavy metals.
Vaccination of 27- to 45-year-olds ("mid-adults") against human papillomavirus (HPV) is less cost-effective than vaccination of younger persons (aged 9 to 26 years).
The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.
Risk for all-cause mortality and MACEs are affected by calcified and low-attenuation plaque burdens in patients with chronic kidney disease.